Literature DB >> 19638468

Persuading natural killer cells to eliminate bad B cells.

Laurence J N Cooper1.   

Abstract

Clinical trials are underway infusing T cells genetically modified to be specific for B-cell malignancies using a chimeric antigen receptor (CAR) to redirect specificity for CD19. However, issues remain about whether the CAR can provide a fully competent application signal and whether other lymphocytes with lytic capacity can target CD19(+) tumors.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19638468      PMCID： PMC2730884          DOI： 10.1158/1078-0432.CCR-09-0966

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

2.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Authors:  Claudia M Kowolik; Max S Topp; Sergio Gonzalez; Timothy Pfeiffer; Simon Olivares; Nancy Gonzalez; David D Smith; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

Review 3.  The T-body approach: potential for cancer immunotherapy.

Authors:  Z Eshhar; N Bach; C J Fitzer-Attas; G Gross; J Lustgarten; T Waks; D G Schindler
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

Authors:  Loredana Ruggeri; Antonella Mancusi; Marusca Capanni; Elena Urbani; Alessandra Carotti; Teresa Aloisi; Martin Stern; Daniela Pende; Katia Perruccio; Emanuela Burchielli; Fabiana Topini; Erika Bianchi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

5.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Authors:  Jeffrey S Miller; Yvette Soignier; Angela Panoskaltsis-Mortari; Sarah A McNearney; Gong H Yun; Susan K Fautsch; David McKenna; Chap Le; Todd E Defor; Linda J Burns; Paul J Orchard; Bruce R Blazar; John E Wagner; Arne Slungaard; Daniel J Weisdorf; Ian J Okazaki; Philip B McGlave
Journal:  Blood       Date:  2005-01-04       Impact factor: 22.113

6.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

7.  NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.

Authors:  Stefan Diermayr; Heike Himmelreich; Bojana Durovic; Arina Mathys-Schneeberger; Uwe Siegler; Ulrich Langenkamp; Jan Hofsteenge; Alois Gratwohl; André Tichelli; Monika Paluszewska; Wieslaw Wiktor-Jedrzejczak; Christian P Kalberer; Aleksandra Wodnar-Filipowicz
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

8.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Authors:  Michael C Milone; Jonathan D Fish; Carmine Carpenito; Richard G Carroll; Gwendolyn K Binder; David Teachey; Minu Samanta; Mehdi Lakhal; Brian Gloss; Gwenn Danet-Desnoyers; Dario Campana; James L Riley; Stephan A Grupp; Carl H June
Journal:  Mol Ther       Date:  2009-04-21       Impact factor: 11.454

9.  Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

Authors:  Harjeet Singh; Pallavi R Manuri; Simon Olivares; Navid Dara; Margaret J Dawson; Helen Huls; Perry B Hackett; Donald B Kohn; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  What is the role for donor natural killer cells after nonmyeloablative conditioning?

Authors:  Frédéric Baron; Effie W Petersdorf; Ted Gooley; Brenda M Sandmaier; Mari Malkki; Thomas R Chauncey; David G Maloney; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2009-05       Impact factor: 5.742
View more
  1 in total

Review 1.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.